Authority Note: R303-93; reaffirmed R101-03; reaffirmed sub R101-08; reaffirmed R103-13; reaffirmed R101-18; reaffirmed R101-19 121.07 Eligibility, Benefits & Coverage - Reference Pricing The LSMS policy is to advocate for the inclusion of the concept of a schedule of benefits/provider fee schedule system with balance billing as one option in a pluralistic array of choices regardless of whether it is called Benefit Payment Schedule, Reference Pricing, Fixed Indemnity or some other than current name so long as the plan is free to establish its payments, physicians are free to establish their fees and patients and physicians are free to determine how to resolve any difference between payments and fees. Authority Note: Added R408-14; reaffirmed R101-19 124.01 Prescriptions - Regulate and License Pharmacy Benefit Managers in Louisiana The LSMS supports the Louisiana Department of Insurance having oversight regarding the actions of PBMs providing services to Louisianans so that PBMs are held accountable for their actions in the pricing, management and dispensing of medications to Louisianans. Authority Note: R204-19 150.02 Medicaid - Physician Freedom to Accept Medicaid The LSMS opposes any effort to impose a penalty on a physician for declining to accept Medicaid patients. Authority Note: Added R404-14 ; reaffirmed R101-19 170.01 Medical Marijuana - General Policy The policy of the LSMS relative to medical marijuana calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease. LSMS urges that marijuana’s status as a federal schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. LSMS supports federally developed legislation requiring warning labels on all cannabis products not approved by the U.S. Food and Drug Administration for preventing or treating any disease process. Authority Note: Added R205-14; amended R101-19 242.01 Environmental Health - UV Tanning The LSMS supports the FDA warning that UVA tanning booths and sunbeds pose potential significant health risks and should be discouraged. The LSMS endorses an educational campaign regarding the skin health and aging hazards of UVA overexposure, in particular from tanning parlor facilities. The LSMS opposes the use of indoor tanning devices by minors as devices emit UVA and UVB radiation and because overexposure to UV radiation can lead to the development of skin cancer. Authority Note: R36-89; reaffirmed 1999; reaffirmed R101-06; reaffirmed R101-11; amended R301- 14; reaffirmed R101-19
Made with FlippingBook Digital Publishing Software